The gap in the hip OA treatment pathway

For many people living with moderate-to-severe hip osteoarthritis, there comes a point where the standard options feel inadequate. Corticosteroid injections that once gave a few months of relief are no longer working — and yet hip replacement surgery, with its recovery demands and finite implant lifespan, does not feel like the right step yet. This gap is where a great many patients find themselves, and it is the clinical problem this article addresses.

The evidence supporting conventional hip injections has real limits. A 2025 systematic review and meta-analysis found that intra-articular corticosteroids for hip OA produced no statistically significant improvement over placebo on WOMAC pain scores at two months (p = 0.05), and no meaningful advantage over hyaluronic acid at six months (p = 0.46). That is a significant finding: one of the most commonly administered hip injections may offer little beyond a placebo effect in many patients with established osteoarthritis.

Hip replacement remains the definitive end-point, and for patients with end-stage joint destruction it is often the right call. But approximately 58% of total hip replacements are estimated to last 25 years, meaning a patient receiving one in their fifties may face revision surgery in later life. Add to that the rehabilitation burden of a major operation under general or spinal anaesthesia, and it becomes clear why patients with Kellgren-Lawrence Grade III or IV diffuse hip OA — whose conservative care has plateaued — may reasonably want a bridging option explored first.

ChondroFiller injectable collagen scaffold is positioned as an intermediate-pathway treatment for exactly this group. It is not proposed as a substitute for hip replacement when that surgery is clinically indicated and the patient is ready; rather, it is framed as a potential joint-preservation and functional life-extension option for patients caught between failing injections and surgery they are not yet ready to accept. Lincolnshire Hip works with patients at this stage of their decision-making, helping them understand what each pathway realistically involves.

What ChondroFiller hip injection involves

ChondroFiller is a CE-marked Class III medical device — a liquid Type I collagen scaffold that, once injected into the hip joint, gels in place to form a soft, viscoelastic cushion over worn articular surfaces. That distinction matters if you have already tried hyaluronic acid or corticosteroid: those treatments address symptoms (lubrication and inflammation respectively) but do not provide any structural layer over damaged cartilage. ChondroFiller works differently — it adds material to the joint rather than removing or replacing anything.

The mechanism is described as acellular matrix-induced chondrogenesis, which in plain terms means the scaffold itself contains no living cells. Instead, it creates favourable conditions in the joint that encourage the patient's own progenitor cells — drawn from the surrounding synovium and subchondral bone — to migrate into the matrix and support the body's own repair processes. The product does not regrow cartilage on its own; it provides the structural environment that may allow endogenous repair to take place.

Because the collagen polymerises rapidly in situ and does not require a dry joint bed, it can be delivered into the fluid environment of the hip without surgical access. The procedure is carried out in an outpatient clinic under local anaesthesia, guided by ultrasound or fluoroscopy to ensure accurate placement. There is no general anaesthetic, no theatre admission, and no incision. For patients who have already exhausted standard injection options, that practical difference in setting — and in the nature of what is being delivered — is the starting point for understanding whether this pathway warrants further discussion.

What the clinical evidence shows for the hip

The most substantial published dataset comes from a 2021 prospective cohort study in the Journal of Hip Preservation Surgery (n=26), in which ChondroFiller gel was delivered arthroscopically into acetabular cartilage defects in adults with femoroacetabular impingement. At three-to-five-year follow-up, 17 of 21 available patients achieved good or excellent outcomes, with modified Harris Hip Score improving by approximately 30 points. Two of the original 26 patients underwent total hip replacement during the study period, confirming that ChondroFiller does not make arthroplasty irrelevant for everyone.

One finding from that same cohort deserves particular weight: patients with pre-existing Tönnis Grade 2–3 osteoarthritis — meaning diffuse, established joint degeneration — had poor results. Since the injectable form is positioned specifically for Kellgren-Lawrence Grade III/IV diffuse hip OA, this raises a genuine planning question. Arthroscopic delivery targets focal, bounded defects; intra-articular injection targets worn surfaces more broadly. These are different routes, addressing different disease patterns, and outcomes from one cannot simply be read across to the other. Published trial data specific to the injectable form in the hip are limited; the evidence base draws on arthroscopic hip studies and the device's use in other joints.

A 2025 case report in JOCR adds a more optimistic data point for younger patients: a 32-year-old active male with a 15 mm × 5 mm osteochondral defect of the femoral head achieved complete pain relief, full range of motion, and normal gait after ChondroFiller application without microfracture, with subchondral bone preserved.

On the broader question of durability, a separate 2025 case report — involving a different biologic hip injection — offers a grounding note: the patient remained pain-free at 12 months but required total hip arthroplasty at 18 months after symptom recurrence. Delay is a realistic and clinically meaningful goal for the right patient; it is not a certainty.

When hip replacement remains the right route

Total hip replacement resolves end-stage hip OA more reliably than any injection-based pathway. For patients who have reached the point of severe functional loss — limited walking distance, rest pain, or near-complete cartilage loss on imaging — it is not a last resort but the most clinically appropriate next step.

The procedure requires a general or spinal anaesthetic, an operating theatre admission, and a structured rehabilitation period measured in weeks before full function returns. For a patient whose daily function has already collapsed, that commitment is proportionate to the gain: a well-performed primary hip replacement reliably eliminates the grinding, constant pain of end-stage joint disease.

Where timing becomes more nuanced is in younger, more active patients. A hip prosthesis has a finite working life, and the clinically significant consequence of that is not the number itself — it is what revision surgery entails. Revision means reopening the joint, removing the existing implant, and fitting new components into bone that has been remodelled by the first procedure. It carries a higher complication rate, greater blood loss, and a more demanding recovery than primary arthroplasty. For a patient in their mid-fifties, the statistical probability of facing that second operation within their lifetime is real. It is that downstream arithmetic — not any reluctance about surgery — that gives joint-preservation strategies their clinical rationale in the right candidate.

Where ChondroFiller injection is clearly unsuitable is when OA has already progressed beyond the point at which preserving native joint function remains viable. An end-stage hip with severe cartilage loss and marked structural change offers no substrate for an additive scaffold to work with. In those patients, timely hip replacement is the more honest and more genuinely helpful recommendation.

Choosing between injection and surgery: the pathway decision

Three questions tend to structure this conversation in clinic: how far has the OA progressed on imaging, how much function does the patient still need to protect, and has the standard injection pathway — corticosteroid or hyaluronic acid — already been tried and found wanting?

The answer to the first question requires imaging. A weight-bearing X-ray confirms Kellgren-Lawrence grading; MRI adds detail on residual cartilage volume and subchondral bone status. Both matter because ChondroFiller injection works additively — it needs something to coat. If imaging shows near-complete cartilage loss with structural joint collapse, there is no viable substrate for a scaffold to engage with, and the honest clinical recommendation shifts toward arthroplasty without further delay.

Where the picture is less clear-cut — moderate-to-advanced OA, some preserved joint space, a patient in their forties or fifties who is still working or physically active — the sequencing question becomes genuinely open. ChondroFiller injection in that setting is not framed as a way to avoid surgery; it is a way to make the timing of surgery a considered choice rather than an emergency. A patient who gains two to three years of improved function before requiring hip replacement has lost nothing and gained meaningful quality of life in the interim.

What ChondroFiller injection cannot offer is structural reconstruction. Patients who enter the pathway expecting a rebuilt joint will likely be disappointed; patients who enter it expecting pain relief, better cushioning, and a window of preserved function are working with realistic expectations.

A clinical assessment with current imaging is the natural starting point. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

Getting an assessment at Lincolnshire Hip

Deciding between a collagen scaffold injection and early hip replacement cannot be made from an article alone — it depends on imaging findings, functional history, and the patient's own priorities. A clinical assessment gives those factors concrete shape.

At Lincolnshire Hip, an assessment typically covers clinical history, a review of current imaging, and a frank discussion of where the joint sits on the OA-severity spectrum. Prof Paul Y. F. Lee, who has published on non-surgical hip pain management, leads the service from Sleaford and Grantham. The outcome of an assessment is a clear recommendation — whether that points toward injection, joint preservation, or arthroplasty — rather than a default to any one pathway. It clarifies the decision; it does not make it on the patient's behalf.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

1. [1] Pain management of hip osteoarthritis with corticosteroids vs injection therapies: a systematic review and meta-analysis. (2025). https://doi.org/10.1186/s12891-025-08666-0 https://doi.org/10.1186/s12891-025-08666-0
2. [2] Cartilage Repair and Symptom Relief After Autologous Microfragmented Adipose-Derived Mesenchymal Stem Cell Therapy in Hip Osteoarthritis: A Case Report with Histological Correlation. (2025). https://doi.org/10.2174/011574888X388459250915055552 https://doi.org/10.2174/011574888X388459250915055552
3. [3] Outcomes of surgical hip dislocation combined with bone graft for adolescents and younger adults with osteonecrosis of the femoral head. (2022). https://doi.org/10.1186/s12891-022-05456-w https://doi.org/10.1186/s12891-022-05456-w
4. [4] Arthroscopic utilisation of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
5. [5] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176
6. [6] Hip Chondral Defects: Arthroscopic Treatment With the Needle and Curette Technique and ChondroFiller. (2021). https://doi.org/10.1016/j.eats.2021.03.011 https://doi.org/10.1016/j.eats.2021.03.011